Clinical trials: Glabellar Lines
Glabellar Frown Lines
Safety Study of DWP-450 (Botulinum Purified Neurotoxin, Type A) Injection to Treat Glabellar Lines
The purpose of this study is to demonstrate the safety of multiple doses of DWP-450 (Botulinum purified neurotoxin, Type A) Injection in treatment of moderate to severe glabellar lines in adult subjects.
- Trial name
- EV-004 (NCT02184988)
- Testing
- Botulinum purified neurotoxin, Type A
- Where
- United States
- Volunteers
- 352 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Glabellar Frown Lines
Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006
The primary objective is to demonstrate the safety of multiple doses of DWP-450 purified Botulinum neurotoxin, Type A, in treatment of moderate to severe glabellar lines associated with corrugator and procerus muscle activity in…
- Trial name
- EV-006 (NCT02428608)
- Testing
- DWP-450 (Botulinum purified neurotoxin, Type A)
- Where
- United States
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Facial Rhytides, Glabellar Frown Lines
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Forehead and Frown Lines
This study evaluated the safety and efficacy of botulinum toxin Type A compared to placebo for the treatment of forehead lines (facial rhytides) when also administered to frown lines (glabellar rhytides).
- Trial name
- NCT01391299
- Testing
- botulinum toxin Type A, Normal Saline
- Where
- Canada
- Volunteers
- 175 people
- Sponsor
- Allergan
Glabellar Lines
Safety and Efficacy of Two Types of Botulinum Toxin Type A For the Treatment of Glabellar Lines
This study will evaluate the safety and efficacy of two different types of botulinum toxin type A for the treatment of glabellar frown lines.
- Trial name
- NCT01271452
- Testing
- botulinum toxin type A
- Where
- Germany
- Volunteers
- 224 people
- Sponsor
- Allergan
Glabellar Frown Lines
Treatment of Moderate to Severe Glabellar Lines
The objective of the study is to evaluate the efficacy and safety of a single dose of QM1114-DP compared to placebo for the treatment of moderate to severe GL.
- Trial name
- READY-1 (NCT04249583)
- Testing
- botulinum toxin
- Where
- 14 sites in United States, Canada
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Hyperhidrosis, Muscle Spasticity
Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) in Korea
This post marketing surveillance study in Korea will evaluate the safety and efficacy of BOTOX (botulinum toxin Type A) in patients who receive treatment according to standard of care for primary axillary hyperhidrosis, focal…
- Conditions
- Hyperhidrosis, Muscle Spasticity, Glabellar Lines
- Trial name
- NCT02043145
- Testing
- botulinum toxin Type A
- Where
- South Korea
- Volunteers
- 727 people
- Sponsor
- Allergan
Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines)
Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial Lines
This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of DaxibotulinumtoxinA for injection (DAXI for injection) in the treatment of Glabellar Lines (GL), Dynamic Forehead Lines (FHL)…
- Trial name
- NCT04259086
- Testing
- DaxibotulinumtoxinA for injection
- Where
- 8 sites in United States, Canada
- Volunteers
- 48 people
- Sponsor
- Revance Therapeutics, Inc.
Glabellar Frown Lines
Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study II
The aim of this study is to assess the efficacy and safety of BoNT/a-DP in the treatment of glabellar lines in comparison with placebo, including efficacy after repeat treatments and long term safety.
- Trial name
- BLESS-II (NCT02677805)
- Testing
- Botulinum Toxin A, Botulinum Toxin A - Open Label
- Where
- 7 sites in United States
- Volunteers
- 251 people
- Sponsor
- Croma-Pharma GmbH
Moderate to Severe Glabellar Lines
Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines
The purpose of this study was to demonstrate the safety and the efficacy of a single treatment of an injectable liquid form of Clostridium botulinum toxin type A haemagglutinin complex (BTX-A-HAC; hereafter referred to as…
- Trial name
- BTX-A-HAC NG (NCT02353871)
- Testing
- Botulinum toxin type A
- Where
- 9 sites in France, Germany
- Volunteers
- 185 people
- Sponsor
- Ipsen
Frown Lines
Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Forehead Lines (Frontalis)
This is a phase 2a, multicenter, open-label, dose-escalation study to evaluate treatment of moderate or severe dynamic forehead lines (FHL) (frontalis) in conjunction with treatment of the glabellar complex.
- Trial name
- NCT03786770
- Testing
- DaxibotulinumtoxinA for injection
- Where
- 4 sites in United States, Canada
- Volunteers
- 61 people
- Sponsor
- Revance Therapeutics, Inc.
Glabellar Lines
A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines
Hyperfunctional facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin.
- Trial name
- NCT05013424
- Testing
- Formulation A: OnabotulinumtoxinA, Formulation B: OnabotulinumtoxinA, Formulation C: OnabotulinumtoxinA
- Where
- 5 sites in United States
- Volunteers
- 92 people
- Sponsor
- Allergan
Glabellar Frown Lines
Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines
An interventional phase 2 study to evaluate safety and efficacy of AbobotulinumtoxinA treatment for glabellar lines
- Trial name
- NCT03736928
- Testing
- AbobotulinumtoxinA dose level 1 or 2, AbobotulinumtoxinA dose 3, AbobotulinumtoxinA dose 4
- Where
- 10 sites in United States
- Volunteers
- 401 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Glabellar Frown Lines
Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines
The purpose of this study is to demonstrate the safety and duration of effect of 40 Units of prabotulinumtoxinA-xvfs (Jeuveau®) in providing temporary improvement in the appearance of moderate to severe glabellar lines (frown…
- Trial name
- NCT05320393
- Testing
- PrabotulinumtoxinA-Xvfs, OnabotulinumtoxinA
- Where
- United States
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Glabellar Frown Lines
AI-09 In Subjects With Glabellar Lines, GL-101
AI-09 In Subjects with Glabellar Lines
- Trial name
- NCT05565950
- Testing
- AI-09, Vehicle
- Where
- 4 sites in United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Eirion Therapeutics Inc.
Glabellar Frown Lines
A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001
The primary objective is to demonstrate the safety and efficacy of DWP-450 (Botulinum purified neurotoxin, Type A) Injection in the treatment of moderate to severe glabellar lines associated with corrugator and/or procerus muscle…
- Trial name
- NCT02334423
- Testing
- Botulinum toxin, Type A, 0.9% sterile, unpreserved saline
- Where
- United States
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Glabellar Lines
AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines
The purpose of this study is to evaluate the safety and efficacy of AGN-151586 over a range of doses for the treatment of moderate to severe glabellar lines (GL).
- Trial name
- NCT04096326
- Testing
- AGN-151586
- Where
- 9 sites in United States
- Volunteers
- 198 people
- Sponsor
- Allergan
Facial Rhytides, Crow's Feet Lines
Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)
A study to evaluate patient satisfaction, aesthetic and psychological impact of combined treatment with BOTOX® Cosmetic (onabotulinumtoxinA), JUVÉDERM® ULTRA XC, JUVÉDERM® ULTRA PLUS XC, JUVÉDERM® VOLUMA® XC, and LATISSE®…
- Conditions
- Facial Rhytides, Crow's Feet Lines, Glabellar Lines, Nasolabial Fold
- Trial name
- NCT02176356
- Testing
- onabotulinumtoxinA, bimatoprost ophthalmic solution 0.03%, JUVÉDERM® ULTRA XC
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- Allergan
Glabellar Lines
MT10109L in the Treatment of Glabellar Lines
To evaluate the safety and efficacy of MT10109L in the treatment of glabellar lines (GL) in participants with moderate to severe GL.
- Trial name
- NCT03795922
- Testing
- MT10109L
- Where
- 15 sites in United States, Belgium and 1 more
- Volunteers
- 234 people
- Sponsor
- Medy-Tox
Glabellar Lines, Lateral Canthal Lines
MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)
To evaluate the long-term safety of MT10109L in the treatment of GL and/or LCL in participants with moderate to severe GL and/or LCL.
- Trial name
- NCT04157686
- Testing
- MT10109L Dose 1, MT10109L Dose 2, MT10109L Dose 1 + Dose 2
- Where
- 38 sites in United States, Belgium and 4 more
- Volunteers
- 957 people
- Sponsor
- Medy-Tox
Glabellar Lines
Non-interventional Study, Long Term Treatment on Glabellar Lines With Dysport® in Subjects of Chinese Origin
This is a prospective, longitudinal, non-interventional, multi-center study to collect subject and physician satisfaction, and treatment experience with Dysport in real clinical practice in subjects of Chinese origin.
- Trial name
- NCT05089357
- Testing
- AbobotulinumtoxinA
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Galderma R&D